COVID-associated arthritis after severe and non-severe COVID-19: A systematic review.

COVID-19 severity COVID-associated arthritis inflammatory arthritis reactive arthritis

Journal

Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460

Informations de publication

Date de publication:
10 2023
Historique:
revised: 03 09 2023
received: 15 05 2023
accepted: 22 09 2023
medline: 1 11 2023
pubmed: 31 10 2023
entrez: 31 10 2023
Statut: ppublish

Résumé

Since the coronavirus outbreak became a global health emergency in 2020, various immune-based effects, such as inflammatory arthritis (IA), have been recorded. This study aimed to determine the role of COVID-19 severity on post-COVID arthritis. We systematically reviewed 95 patients who developed arthritis after severe and non-severe COVID-19 infection by searching the databases, including PubMed, SCOPUS, and EMBASE. We used the term "COVID-associated arthritis" because there was no definite diagnostic method for classifying arthritides after COVID-19 infection, and the diagnosed arthritis types were based on the authors' viewpoints. After evaluating the data between the two severe and non-severe COVID-19-infected groups of patients, the results showed that the COVID-19 severity may affect the pattern of joint involvement in IA. In both groups, combination therapy, including oral nonsteroidal anti-inflammatory drugs with different types of corticosteroids, was the most common treatment. In addition, the mean age and comorbidities rate was higher in the severe COVID-19 group. Even though the patients in the severe COVID-19 group developed more serious COVID-19 symptoms, they experienced milder arthritis with better outcomes and more delayed onsets that required less aggressive therapy. We conclude that there may be an inverse relationship between COVID-19 severity and arthritis severity, possibly due to weaker immunity conditions following immunosuppressant treatments in patients with severe COVID-19.

Identifiants

pubmed: 37904701
doi: 10.1002/iid3.1035
pmc: PMC10566449
doi:

Substances chimiques

Immunosuppressive Agents 0

Types de publication

Systematic Review Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1035

Informations de copyright

© 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.

Références

Clin Rheumatol. 2021 Aug;40(8):3357-3362
pubmed: 33587197
Cureus. 2021 Sep 20;13(9):e18139
pubmed: 34692347
BMC Rheumatol. 2020 Oct 28;4:65
pubmed: 33123675
Ann Rheum Dis. 2021 Aug;80(8):1096-1098
pubmed: 33648960
Reumatol Clin. 2023 Feb;19(2):67-73
pubmed: 35578636
Arthritis Care Res (Hoboken). 2011 Nov;63(11):1565-70
pubmed: 21954118
Ann Rheum Dis. 2021 Jun;80(6):e91
pubmed: 32632032
Acta Reumatol Port. 2020 Oct-Dec;45(4):278-280
pubmed: 33420769
Clin Case Rep. 2022 Feb 07;10(2):e05430
pubmed: 35154733
North Clin Istanb. 2021 Aug 25;8(4):423-424
pubmed: 34585082
RMD Open. 2022 Sep;8(2):
pubmed: 36100294
J Clin Rheumatol. 2020 Sep;26(6):233
pubmed: 32694352
Ann Rheum Dis. 2023 Apr;82(4):e86
pubmed: 32753423
Indian J Pediatr. 2022 Jan;89(1):103
pubmed: 34687437
Clin Exp Rheumatol. 2023 Mar;41(3):656-666
pubmed: 35916289
Pediatr Rheumatol Online J. 2021 Jun 12;19(1):89
pubmed: 34118941
Lancet Rheumatol. 2020 Sep;2(9):e518-e519
pubmed: 32838313
Ann Rheum Dis. 2021 Apr;80(4):e58
pubmed: 32471899
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
Cureus. 2020 Aug 12;12(8):e9698
pubmed: 32923288
Clin Exp Rheumatol. 2021 Jan-Feb;39 Suppl 128(1):25-26
pubmed: 33506755
RMD Open. 2022 Sep;8(2):
pubmed: 36096524
Lancet Rheumatol. 2020 Nov;2(11):e655-e657
pubmed: 33043303
Joint Bone Spine. 2020 Dec;87(6):660
pubmed: 32622040
Infection. 2023 Feb;51(1):37-45
pubmed: 35655110
Reumatol Clin (Engl Ed). 2022 Oct;18(8):490-492
pubmed: 35562296
Clin Rev Allergy Immunol. 2012 Feb;42(1):102-11
pubmed: 22095454
RMD Open. 2020 Aug;6(2):
pubmed: 32763956
J Infect Chemother. 2022 Apr;28(4):587-590
pubmed: 35016827
Indian J Hematol Blood Transfus. 2023 Jan;39(1):154-155
pubmed: 36699433
Medicine (Baltimore). 2021 Jun 11;100(23):e26089
pubmed: 34114992
Trop Dis Travel Med Vaccines. 2021 Jun 15;7(1):18
pubmed: 34130744
Viruses. 2021 Aug 06;13(8):
pubmed: 34452422
Rheumatol Adv Pract. 2021 Feb 04;5(1):rkab001
pubmed: 33615130
Cureus. 2022 Apr 13;14(4):e24096
pubmed: 35573487
Rheumatol Int. 2021 Nov;41(11):2031-2039
pubmed: 34550429
Cureus. 2021 Oct 9;13(10):e18620
pubmed: 34765373
Immunology. 2020 Jul;160(3):261-268
pubmed: 32460357
Reumatismo. 2021 Apr 19;73(1):59-63
pubmed: 33874649
Rheumatology (Oxford). 2021 Jul 1;60(7):e232-e233
pubmed: 33471106
Cureus. 2020 Nov 28;12(11):e11761
pubmed: 33409010
Clin Case Rep. 2020 Nov 16;9(1):304-308
pubmed: 33362924
Clin Rheumatol. 2022 Jun;41(6):1641-1652
pubmed: 35247132
Immun Inflamm Dis. 2021 Sep;9(3):628-631
pubmed: 33979033
BMJ Glob Health. 2021 Dec;6(12):
pubmed: 34916273
Adv Respir Med. 2021;89(2):135-144
pubmed: 33966261
Ann Rheum Dis. 2021 Jun;80(6):e101
pubmed: 32591356
J Med Virol. 2021 Jan;93(1):192-193
pubmed: 32652541
BMJ Case Rep. 2021 Mar 2;14(3):
pubmed: 33653867

Auteurs

Mahsa Zarpoosh (M)

Kermanshah University of Medical Science (KUMS), Kermanshah, Iran.

Parsa Amirian (P)

Kermanshah University of Medical Science (KUMS), Kermanshah, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH